Phase 3 Investigation of Ampreloxetine Produces Positive Results for Neurogenic Orthostatic Hypotension
Theravance Biopharma Inc. has just released results from their 2nd Phase 3 investigation of Ampreloxetine as a therapy for symptomatic neurogenic orthostatic hypotension (nOH). Symptomatic nOH NOH is a rare…